Enlivex Therapeutics (ENLV) Competitors $1.36 +0.01 (+0.74%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends ENLV vs. IVVD, RANI, INMB, PDSB, IMUX, ME, IPSC, OPTN, ANRO, and DERMShould you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Invivyd (IVVD), Rani Therapeutics (RANI), INmune Bio (INMB), PDS Biotechnology (PDSB), Immunic (IMUX), 23andMe (ME), Century Therapeutics (IPSC), OptiNose (OPTN), Alto Neuroscience (ANRO), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry. Enlivex Therapeutics vs. Invivyd Rani Therapeutics INmune Bio PDS Biotechnology Immunic 23andMe Century Therapeutics OptiNose Alto Neuroscience Journey Medical Invivyd (NASDAQ:IVVD) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation. Is IVVD or ENLV more profitable? Enlivex Therapeutics' return on equity of -71.76% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets InvivydN/A -109.72% -90.91% Enlivex Therapeutics N/A -71.76%-60.78% Do analysts prefer IVVD or ENLV? Invivyd currently has a consensus price target of $11.33, indicating a potential upside of 1,140.51%. Enlivex Therapeutics has a consensus price target of $6.00, indicating a potential upside of 341.18%. Given Invivyd's higher possible upside, equities analysts plainly believe Invivyd is more favorable than Enlivex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invivyd 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the media prefer IVVD or ENLV? In the previous week, Invivyd had 8 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 10 mentions for Invivyd and 2 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.33 beat Invivyd's score of 0.31 indicating that Enlivex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in IVVD or ENLV? Enlivex Therapeutics received 41 more outperform votes than Invivyd when rated by MarketBeat users. Likewise, 79.10% of users gave Enlivex Therapeutics an outperform vote while only 75.00% of users gave Invivyd an outperform vote. CompanyUnderperformOutperformInvivydOutperform Votes1275.00% Underperform Votes425.00% Enlivex TherapeuticsOutperform Votes5379.10% Underperform Votes1420.90% Which has more volatility & risk, IVVD or ENLV? Invivyd has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Which has better valuation & earnings, IVVD or ENLV? Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvivydN/AN/A-$198.64M-$1.81-0.50Enlivex TherapeuticsN/AN/A-$29.07M-$1.18-1.15 Do insiders & institutionals have more ownership in IVVD or ENLV? 70.4% of Invivyd shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 17.9% of Invivyd shares are owned by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryEnlivex Therapeutics beats Invivyd on 9 of the 15 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENLV vs. The Competition Export to ExcelMetricEnlivex TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.12M$7.02B$5.33B$8.52BDividend YieldN/A7.92%5.07%4.13%P/E Ratio-1.1512.34128.5116.13Price / SalesN/A401.661,489.1693.42Price / CashN/A47.4339.6734.18Price / Book0.845.604.765.07Net Income-$29.07M$153.56M$119.00M$225.46M7 Day Performance-7.48%0.13%0.79%0.54%1 Month Performance-12.26%15.20%5.64%3.75%1 Year Performance-3.55%41.11%36.71%29.48% Enlivex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENLVEnlivex Therapeutics3.3974 of 5 stars$1.36+0.7%$6.00+341.2%+2.4%$29.11MN/A-1.1570News CoverageIVVDInvivyd2.4769 of 5 stars$1.04+7.2%$11.33+989.7%-37.9%$124.09M$2.26M-0.57100Analyst ForecastNews CoverageRANIRani Therapeutics3.1546 of 5 stars$2.31-1.3%$11.71+407.1%+20.9%$123.38M$2.72M-1.96110Gap UpHigh Trading VolumeINMBINmune Bio2.3312 of 5 stars$6.17+13.9%$20.00+224.4%-14.6%$121.82M$160,000.00-2.9910Short Interest ↑News CoverageGap UpHigh Trading VolumePDSBPDS Biotechnology0.8486 of 5 stars$3.30+5.8%$14.25+331.8%-23.4%$121.51MN/A-2.7020Analyst UpgradeIMUXImmunic2.5679 of 5 stars$1.34-3.6%$11.20+735.8%+14.4%$120.71MN/A-0.8970News CoverageME23andMe1.9247 of 5 stars$4.85+3.9%$9.40+93.8%-71.6%$118.87M$219.64M-0.19770Gap DownIPSCCentury Therapeutics1.768 of 5 stars$1.40+0.7%$12.75+810.7%-15.4%$118.30M$2.04M-0.69170Positive NewsOPTNOptiNose3.411 of 5 stars$0.78+1.3%$4.00+410.5%-45.7%$118.14M$70.99M-2.18190Gap DownANROAlto Neuroscience2.3264 of 5 stars$4.22-3.4%$24.40+478.2%N/A$117.48M$210,000.000.00N/ADERMJourney Medical3.4208 of 5 stars$6.00+4.2%$9.38+56.3%N/A$115.28M$77.68M-300.0090Upcoming EarningsShort Interest ↓ Related Companies and Tools Related Companies IVVD Competitors RANI Competitors INMB Competitors PDSB Competitors IMUX Competitors ME Competitors IPSC Competitors OPTN Competitors ANRO Competitors DERM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ENLV) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
